Anagnostics said this week that it has tapped fellow Austrian firm Vela Laboratories to be its first service partner. Vienna-based Vela will now offer its pharmaceutical and biotech clients the ability to use Anagnostics' cylindrical HybCell microarray platform.
Andreas Nechansky, chief operating officer at Vela, said in a statement that Anagnostics' technology "provides completely new solutions for analytics" that he expects to be of interest to the company's customers. He said the partnership will allow both companies to serve customers "more efficiently as well as on a larger scale."
Vela is a Good Manufacturing Processes-certified contract laboratory that provides pharmas and biotechs with protein screening services, allowing them to better characterize biopharmaceuticals, biologics, and biosimilars.
St. Valentin-based Anagnostics' Hybcell arrays are composed of detector molecules — DNA or proteins — which are immobilized on the surface of an inner cylinder that is enclosed within a cylindrical container. Users can fill this external cylinder with sample, and up to 96 Hybcell arrays can be processed at a time in the company's Hyborg system, which integrates a thermal cycler, a hybridization station, and a scanner.
In January, Vela announced that was working with Anagnostics to develop a method for detecting KRAS2 and BRAF mutations using the HybCell platform. Anagnostics announced its plan to launch KRAS and BRAF assays last year (BAN 10/26/2010).